TORONTO, ON — January 8, 2026 — Leads & Copy — NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc. (AIML), has entered into a Commercial Agreement Term Sheet with Lakeshore Cardiology to integrate NeuralCloud’s CardioYield™ AI visualization platform into Lakeshore Cardiology’s clinical workflows.
The agreement, finalized on December 12, 2025, will see CardioYield™, powered by MaxYield™ signal-processing technology, used for Holter monitoring and ambulatory patient workflow. The partnership aims to streamline data review and enable faster, more consistent interpretation of cardiac signals, supporting clinical decision-making.
Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AIML, stated that the agreement highlights NeuralCloud’s commitment to bringing AI-driven ECG analysis into clinical practice. Martina Magnotta, Manager of Operations of Lakeshore Cardiology, commented that partnering with NeuralCloud allows them to bring AI-enhanced insights into their Holter monitoring processes.
Paul Duffy, Executive Chairman and CEO of AIML, noted that the collaboration highlights the growing adaptability of NeuralCloud’s AI platform across clinical environments.
CardioYield™ is an AI-powered ECG visualization and reporting platform that uses MaxYield™, NeuralCloud’s proprietary, patent-pending signal-processing engine. The platform enables the review of enhanced Holter and other ECG signals through a user-friendly interface, highlights PQRST intervals and waveform morphology, automates the grouping of conditions and abnormalities, and provides end-to-end Holter report generation designed to meet clinical workflow standards.
MaxYield™ isolates and labels key waveform components, including P waves, QRS complexes, and T waves, producing clean, machine-readable, beat-by-beat interval data suitable for downstream analytics and reporting.
The agreement outlines a staged rollout of CardioYield™, beginning with an internal validation using representative Holter files, followed by a limited paid trial within Lakeshore Cardiology to test the platform in real-world workflows. Once validated, the solution will be integrated into the clinic’s systems, with full deployment and cloud-based setup. Finally, pending Health Canada clearance, CardioYield™ will be commercially available for use across Lakeshore Cardiology’s cardiac monitoring operations.
Lakeshore Cardiology specializes in consultative, non-invasive diagnostic cardiology, combining state-of-the-art diagnostic equipment with a compassionate approach. Their team includes Royal College of Physicians and Surgeons of Canada-certified specialists, registered cardiovascular technicians, cardiac sonographers, and nurses.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. AIML’s shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
Contact:
Blake Fallis (778) 405-0882
Source: AI/ML Innovations Inc.
